title: Recurrent longitudinal myelitis as primary manifestation of SLE.
authors.forename: F-G
authors.initials: FG
authors.lastname: Lehnhardt
authors.forename: P
authors.initials: P
authors.lastname: Impekoven
authors.forename: A
authors.initials: A
authors.lastname: Rubbert
authors.forename: L
authors.initials: L
authors.lastname: Burghaus
authors.forename: M
authors.initials: M
authors.lastname: Neveling
authors.forename: W-D
authors.initials: WD
authors.lastname: Heiss
authors.forename: A H
authors.initials: AH
authors.lastname: Jacobs
mesh_terms: D000328:Adult; D016736:Antiphospholipid Syndrome / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008279:Magnetic Resonance Imaging; D008775:Methylprednisolone / Q000627:therapeutic use; D009187:Myelitis / Q000209:etiology* / Q000473:pathology; D012008:Recurrence; D012074:Remission Induction
chemical_list: D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D008775:Methylprednisolone